Microsoft Word – ICBI Press Release June 9, 2015 Final
BEVERLY HILLS, CA, United States, via ETELIGIS INC., 06/09/2015 – – ICB International Inc., (“ICBI or ICBII”), launches Blood-Brain Barrier crossing SMART Molecule platform technology and engages Alan Morell, Creative Management Partners as Senior Advisor.
There are currently no diagnostics and disease altering therapeutics for Alzheimer’s or Parkinson’s disease, which afflict more than 54 million patients worldwide. One of the main reasons for the lack of diagnostic tests and disease modifying treatments for brain disorders is the impermeability of the blood-brain barrier (BBB). ICBI has developed a proprietary SMART Molecule (SM) platform technology (SMART = Specific Molecular Architecture for Recognition and Therapy) that is unique in its ability to cross the blood-brain barrier (BBB) and to permeate cell membranes. SMs enable noninvasive diagnoses and treatment of neuro-degenerative diseases (Parkinson’s and Alzheimer’s) and multiple cancers (brain, breast, colorectal and prostate). External laboratories have validated SM technology and ICBI is currently in the process of scaling up for phase 1 clinical trials in Parkinson’s and Alzheimer’s using SMs.
SMs Cross the Blood-Brain Barrier:
The BBB, discovered by Nobel Laureate, Dr. Paul Ehrlich, in 1885, is a physical barrier that allows essential nutrients to enter the brain but blocks viruses, bacteria, parasites and 98% of all drugs [The Amer. Soc. Exp. Neuro Ther., 2, 3(2015)]. ICBII’s SMs are proprietary antibody mimics that efficiently cross the BBB into the CNS and target specific pathological lesions in the brain. They have a 50 to 150 fold higher BBB permeability than reported for conventional mouse monoclonal antibodies (mAb). The Michael J. Fox Foundation has recognized and supported ICBII’s development of SMs.
SM Technology Overcomes Conventional Barriers to Treatment for Complex CNS Disease:
SM technology enables delivery of drugs to the brain with an intravenous injection. In addition, 1) SMs pass through the BBB and cell walls; 2) simultaneously target disease specific proteins; 3) SMs are capable of targeting more than one target with the same SM instead of the more common current single antigen approach; and 4) have a half-life of more than seven days in terms of retention in the blood stream. Because SMs attach to specific targets with greater permeability, efficacy is potentially improved while side effects and toxicity are reduced.
SM is a Platform Technology:
The Smart Molecule design at the core of ICBII’s technology enables rapid customization and development of new therapies for a wide range of complex diseases that include diseases of the CNS (e.g., Alzheimer’s and Parkinson’s) but also the treatment of various cancers, including brain, breast, colorectal, lung, prostate, and ovarian, as well as Age-Related Macular Degeneration (AMD).
Said Dr. Ram Bhatt, Founder/CEO: “ICBII has developed a proprietary SMART Molecule (SM) platform technology that is unique in its ability to cross the blood-brain-barrier (BBB) and to diagnose and develop disease modifying therapies for neurodegenerative diseases which has not been possible so far. Our technology complements the research efforts of big pharma and we are very pleased to be working with Mr. Morell to ensure that the potential of our technology is presented at the highest levels of Pharma decision makers.”
Said Dr. Arvind Bhambri, Strategy Officer: “ICBII SM is a Platform Technology with transformative potential. We required at our stage, an expert to position ICBII in the market place with Fortune 500 decision makers and, in the short time that we have worked with Alan, we have already started to see what makes him a superstar. Ultimately, our mission is to partner with those companies that can make best use of our platform technology to benefit millions of Alzheimer’s, Parkinson’s, and cancer patients throughout the world.”
Said Senior Advisor Alan Morell: “ICBII’s business model is ideal for investment and their management, credentials and dedication under founder and CEO Dr. Ram Bhatt and strategy officer, Dr. Arvind Bhambri are impeccable. Though the method at the heart of designing SMs for each disease category is unique and proprietary, manufacturing of individual SMs is scalable through established cloning techniques. This provides ICBII with opportunities for partnering separately in each therapeutic category with the pharmaceutical companies that are leaders in that space”.
This press release may contain forward-looking statements. These statements may relate to, among other things, the potential of the SMART Molecules Technology, to the development of diagnostic tests and disease-modifying therapeutics for neurodegenerative diseases and other diseases. These statements are based on in-vivo proof-of-concept data that may prove not to be accurate, and could differ materially from those anticipated from future pre-clinical and clinical trials due to known and unknown risks, uncertainties and other factors beyond our control. ICBI or agent Alan Morell undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in company’s expectations.
THE CREATIVE MANAGEMENT AGENCY
Creative Management Partners LLC
433 North Camden Drive
Beverly Hills, CA. 90210
SOURCE: Creative Management Partners, LLC